Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x100px
Organisation › Details

Oxford Biomedica (Group)

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients. Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners. Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US. *

 

Period Start 1996-01-01 splitoff
  Predecessor University of Oxford
Product Industry gene therapy
Persons Person Mathias, Frank (Oxford Biomedica 202203– CEO before Rentschler + Medigene + Amgen GmbH + Servier DE + Hoechst)
  Person 2 Doliveux, Roch (UCB 200602 CEO)
     
Region Region Oxford, Oxfordshire
  Country United Kingdom (GB)
  Street Building 9400
Oxford Business Park
  City OX4 2HN Oxford, Oxfordshire
  Tel +44-1865-783000
    Address record changed: 2023-12-04
     
Basic data Employees E: 501 to 1,000 (2022-12-31)
  Currency GBP
  Annual sales 139,989,000 (revenue, total, consolidated (2022) 2022-12-31)
  Profit -45,159,000 (2022-12-31)
  Cash 141,285,000 (2022-12-31)
     
    * Document for »About Section«: Oxford Biomedica plc. (11/22/22). "Press Release: Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer". Oxford.
     
   
Record changed: 2024-06-07

Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for Oxford Biomedica (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x300px




» top